The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2022 | Improving guidance on choice of first-line therapy for patients with HCC
Mara Persano, MD, University Of Cagliari, Cagliari, Italy, discusses next steps after a real-world study comparing first-line lenvatinib vs. atezolizumab plus bevacizumab for patients with hepatocellular carcinoma (HCC). A key step will be identifying factors that can guide clinicians in their choice of first-line therapy for these patients. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
